

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K/A

Current report filing [amend]

Filing Date: **2006-01-05** | Period of Report: **2005-12-22**
SEC Accession No. **0001193125-06-001646**

([HTML Version](#) on secdatabase.com)

FILER

RESMED INC

CIK: **943819** | IRS No.: **980152841** | State of Incorpor.: **DE** | Fiscal Year End: **0630**
Type: **8-K/A** | Act: **34** | File No.: **001-15317** | Film No.: **06511806**
SIC: **3841** Surgical & medical instruments & apparatus

Mailing Address
14040 DANIELSON ST
POWAY CA 920646857

Business Address
14040 DANIELSON ST
POWAY CA 920646857
8587462400

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

**FORM
8-K/A**

**AMENDMENT
NO. 1 TO
CURRENT
REPORT
Pursuant to
Section 13 or 15(d)
of the
Securities
Exchange Act of
1934**

Date of Report (Date of
earliest event reported):
December 22, 2005

**ResMed
Inc.**

(Exact Name of Registrant
as Specified in Charter)

Delaware
(State or Other Jurisdiction of
Incorporation)

001-15317
(Commission
File Number)

98-0152841
(I.R.S. Employer
Identification No.)

14040 Danielson Street
Poway, California 92064-6857
(Address of Principal Executive Offices)(Zip Code)

(858) 746-2400
(Registrant' s telephone
number, including area
code)

N/A
(Former Name or Former
Address, if Changed Since
Last Report)

Check the appropriate
box below if the Form
8-K filing is intended to
simultaneously satisfy
the filing obligation of
the registrant under any
of the following
provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ResMed Inc. (the "Company") hereby amends the following item of its Current Report on Form 8-K filed on December 29, 2005 as follows:

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Principal Officer Appointment.

On December 22, 2005, ResMed Inc. announced that Brett Sandercock has been appointed as the Company's Chief Financial Officer effective January 1, 2006. Mr. Sandercock, age 38, replaces Adrian Smith who has received the full-time appointment of the Company's Chief Operating Officer for Europe, a position he has held since November of 2004. Mr. Sandercock joined the Company in 1998 and has held a variety of positions, most recently as Vice President, Treasury and Finance since November of 2004.

Mr. Sandercock's employment with the Company is on an at-will basis and the material terms of his employment arrangement are: base compensation of AUD \$285,000 per year, a performance bonus with a target amount of 40% of base salary, a pension contribution of 9% of base salary and options to purchase 10,000 shares of the Company's common stock at an exercise price of USD \$40.80 per share, which will vest over a period of four years, issued on December 1, 2005.

A copy of the press release relating to the appointment is attached as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits

<u>Exhibits:</u>	<u>Description of Document</u>	
99.1*	Press Release dated December 22, 2005	<hr/>

* Previously filed

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

Date: January 5, 2005

RESMED INC.

(registrant)

By:

/s/ David Pendarvis

Name: David Pendarvis

Its: Global General Counsel, Senior Vice President
Organizational Development and Corporate Secretary

-3-

EXHIBIT INDEX

<u>Exhibits:</u>	<u>Description of Document</u>	_____
99.1*	Press Release dated December 22, 2005	_____
* Previously filed		